With Animal Health and Biotech companies

NanoVet is open to partnering with animal health and biotech companies on the licensing and co-development of nanobody-based therapeutics, with flexible structures ranging from asset-level licensing to broader platform collaborations. We focus on indications where biologics can offer clear advantages over existing treatments, particularly in chronic diseases where cost, scalability, and efficacy are critical.